{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:35Z","timestamp":1793745335714,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.1038\/s41416-025-03286-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:25:01Z","timestamp":1764822301000},"page":"457-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Noboru","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2483-4029","authenticated-orcid":false,"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":false,"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","unstructured":"Bray, F, Laversanne, M, Sung, H, Ferlay, J, Siegel, RL, Soerjomataram, I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2004. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"3286_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18:804\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3286_CR4","doi-asserted-by":"publisher","first-page":"e2133388","DOI":"10.1001\/jamanetworkopen.2021.33388","volume":"4","author":"MJ Raphael","year":"2021","unstructured":"Raphael MJ, Raskin W, Habbous S, Tai X, Beca J, Dai WF, et al. The Association of Drug-Funding Reimbursement with survival outcomes and use of new systemic therapies among patients with advanced pancreatic cancer. JAMA Netw Open. 2021;4:e2133388.","journal-title":"JAMA Netw Open"},{"key":"3286_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"3286_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.","journal-title":"Nat Commun"},{"key":"3286_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48:10\u201318.","journal-title":"Semin Oncol"},{"key":"3286_CR9","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J Clin Oncol. 2023;41:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1200\/JCO.2024.42.3_suppl.604","volume":"42","author":"J Li","year":"2024","unstructured":"Li J, Shen L, Gu Y, Calles A, Wu L, Ba Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol. 2024;42:604.","journal-title":"J Clin Oncol"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1111\/cas.15829","volume":"114","author":"Z Shi","year":"2023","unstructured":"Shi Z, Weng J, Niu H, Yang H, Liu R, Weng Y, et al. D-1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity. Cancer Sci. 2023;114:2951\u201360.","journal-title":"Cancer Sci"},{"key":"3286_CR13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","volume":"18","author":"Z Li","year":"2023","unstructured":"Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, et al. D-1553 (Garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: phase 1 study results. J Thorac Oncol. 2023;18:940\u201351.","journal-title":"J Thorac Oncol"},{"key":"3286_CR14","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1200\/JCO.2023.41.16_suppl.3563","volume":"41","author":"D-y Ruan","year":"2023","unstructured":"Ruan D-y, Lee MA, Deng Y, Lee K-W, Millward M, Grewal JS, et al. Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: results from a phase I\/II study. J Clin Oncol. 2023;41:3563.","journal-title":"J Clin Oncol"},{"key":"3286_CR15","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1016\/j.annonc.2023.09.1741","volume":"34","author":"RH Xu","year":"2023","unstructured":"Xu RH, Xu Y, Yan D, Munster P, Ruan D, Deng Y, et al. 550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study. Ann Oncol. 2023;34:S410\u2013S1.","journal-title":"Ann Oncol"},{"key":"3286_CR16","doi-asserted-by":"publisher","first-page":"S898","DOI":"10.1016\/j.annonc.2023.09.2571","volume":"34","author":"S Kondo","year":"2023","unstructured":"Kondo S, Yan D, Ganju V, Richardson G, Hou X, Shan J, et al. 1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (PCA). Ann Oncol. 2023;34:S898\u2013S899.","journal-title":"Ann Oncol"},{"key":"3286_CR17","doi-asserted-by":"publisher","first-page":"CT246","DOI":"10.1158\/1538-7445.AM2024-CT246","volume":"84","author":"Z Li","year":"2024","unstructured":"Li Z, Dang X, Huang D, Jin S, Li W, Shi J, et al. Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer. Cancer Res. 2024;84:CT246.","journal-title":"Cancer Res"},{"key":"3286_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78\u201387.","journal-title":"Eur J Cancer"},{"key":"3286_CR19","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423\u20139.","journal-title":"J Clin Oncol"},{"key":"3286_CR20","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914\u201320.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03286-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:55:01Z","timestamp":1769615701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03286-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,8]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03286-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NY reports honoraria from Chugai Pharma, Daiichi Sankyo\/UCB Japan, Eisai, reports consulting or advisory fees from Eisai, Boehringer Ingelheim, CMIC, Chugai Pharma, Healios, Merck, Mitsubishi Tanabe, Rakuten Medical Japan, Noile-Immune Biotech, Inc, reports research funding from Chugai Pharma, Taiho Pharmaceutical, Eisai, Astellas Pharma, Novartis, Daiichi Sankyo, Lilly Japan, Boehringer Ingelheim, Takeda, Kyowa Hakko Kirin, Bayer, Pfizer, Ono Pharmaceutical, Janssen, MSD, AbbVie, Bristol Myers Squibb, Merck Serono, GlaxoSmithKline, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab\/Seattle Genetics, Shionogi, Toray Industries, Kaken Pharmaceutical, AstraZeneca, CMIC, InventisBio, Rakuten Medical, Amgen, Bicycle Therapeutics. RES reports grants or contracts from AstraZeneca and Merck; reports consulting fees from GlaxoSmithKline, AstraZeneca, Janssen Oncology, Macrogenics, Daiichi, Sanofi, BeiGene, Gilead, Regeneron, Targeted Oncology, G1 Therapeutics, GE HealthCare, Amgen, and Lilly Oncology; reports payment or honoraria for lectures, presentations from EMD Serono, Illumina, GameOn!, OncLive, Binay Foundation, APP Oncology, and Masters in Thoracic Oncology Summit; participates on advisory board for GlaxoSmithKline, AstraZeneca, Janssen Oncology, Macrogenics, Daiichi, Sanofi, BeiGene, Gilead, Regeneron, Targeted Oncology, G1 Therapeutics, GE HealthCare, Amgen, and Lilly Oncology. ZX, WW, ZS, LZ, YW reports InventisBio employment and stock. R-HX reports speaker fees from Bristol Myers Squibb, Roche, MerckSerono, Hutchison, Hengrui, Junshi, Qilu, CPPC, Henlius, and participates on advisory board for Astellas, MSD, AstraZeneca, Junshi, Hengrui, BeiGene. Innovent, CPPC, and Keymed. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and were approved by the ethics committee of Sun Yat-sen University Cancer Center, and by the ethics committees of the other participating sites. Written informed consent was obtained from all patients prior to screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}